Oncology PracticeFDA Approves Cosibelimab for Cutaneous SCCDecember 17, 2024Nonmelanoma Skin CancerPatient & Survivor CareBusiness of Medicine
Oncology PracticeFDA Approves Durvalumab for Limited-Stage SCLCDecember 6, 2024Lung CancerImmunotherapyPatient & Survivor CarePractice Management
Oncology PracticeFDA Approves Bizengri for NSCLC and Pancreatic Cancers Harboring NRG1 Gene FusionDecember 5, 2024Lung CancerPatient & Survivor CareGastrointestinal CancerMixed TopicsGastroenterology
Oncology PracticeFDA Approves Bispecific HER2 Antibody for Biliary Tract CancerNovember 22, 2024Gastrointestinal CancerGastroenterologyPatient & Survivor Care
Oncology PracticeGotistobart Trial for NSCLC on Partial Clinical HoldOctober 23, 2024Lung CancerPatient & Survivor CarePractice Management
Oncology PracticeFDA OKs Next-Gen Cologuard Test for CRC ScreeningOctober 4, 2024GI OncologyGastroenterologyGastrointestinal Cancer
Oncology PracticeFDA Panel Votes for Limits on Gastric, Esophageal Cancer ImmunotherapySeptember 30, 2024Gastrointestinal CancerGastroenterologyPractice ManagementImmunotherapyPatient & Survivor Care
Oncology PracticeFDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLCSeptember 27, 2024Lung CancerPatient & Survivor CarePractice Management
Oncology PracticeFDA Expands Indication for Amivantamab in Lung CancerSeptember 23, 2024Lung CancerPractice Management
Oncology PracticeFDA OKs Adjuvant Ribociclib in Earlier Stage Breast CancerSeptember 23, 2024Breast CancerPatient & Survivor Care
Oncology PracticeFDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer IndicationsSeptember 17, 2024Mixed TopicsMelanomaLung CancerSarcoma & GISTPatient & Survivor CarePractice Management
Oncology PracticeFDA OKs First-Line Lazertinib With Amivantamab for NSCLCAugust 22, 2024Lung CancerPractice Management
Oncology PracticeFDA Approves Neoadjuvant/Adjuvant Durvalumab for NSCLCAugust 16, 2024Lung CancerPractice Management
Hematology NewsFDA Approves Lymphir for R/R Cutaneous T-Cell LymphomaAugust 9, 2024T Cell LymphomasPatient & Survivor CareBusiness of MedicineImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyPractice Management
Oncology PracticeFDA Approves First Targeted Therapy for Gliomas With IDH MutationsAugust 7, 2024CNS/Brain CancerNeuro-oncology
